Patents Assigned to Merck
  • Mixing device
    Patent number: 12083486
    Abstract: A mixing device (1) for cyclically imparting a force on an external surface (A) of a bag (B) for agitating a content (C) of the bag (B), the mixing device (1) comprising a lever (2) supported so as to be able to pivot about a pivot (3), a weight (4) provided on a first side of the lever (2), a driver (5) arranged to cooperate with the lever (2), a motor (6) for moving the driver (5) to lift the first side of the lever (2) with the weight (4) against gravity and to drop the first side against the external surface (A) of the bag (B), and a holder (7) for supporting the mixing device (1) such that the first side of the lever (2) can contact the external surface (A) of the bag (B) in the drop motion.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: September 10, 2024
    Assignee: Merck Patent GmbH
    Inventors: Stephane Olivier, Gaetan Bour
  • Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
    Patent number: 12083112
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: September 10, 2024
    Assignees: EISAI R&D MANAGEMENT CO., LTD., Merck Sharp & Dohme LLC
    Inventors: Andrew Evan Denker, Yu Kato, Kimiyo Tabata, Yusaku Hori
  • Surface display of whole antibodies in eukaryotes
    Patent number: 12084651
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: September 10, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • GCN2 inhibitors and uses thereof
    Patent number: 12084438
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: September 10, 2024
    Assignees: Merck Patent GmbH, Vertex Pharmaceuticals Incorporated
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • INSULIN RECEPTOR PARTIAL AGONISTS
    Publication number: 20240294596
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: September 7, 2021
    Publication date: September 5, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Dmitri A. Pissarnitski, Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Ravi Nargund, Zhicai Shi, Zhicai Wu, Lin Yan, Yuping Zhu
  • Heteroaromatic isothiocyanates
    Patent number: 12077703
    Abstract: The present invention relates to heteroaromatic isothiocyanates of formula N as defined in claim 1, to liquid-crystalline media comprising one or more compounds of formula N and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: September 3, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Amir Hossain Parham, Constanze Brocke, Carsten Fritzsch, Dagmar Klass
  • Compounds for electronic devices
    Patent number: 12077541
    Abstract: The present application relates to an amine compound according to formula (I), (II) or (III) which is suitable for use in electronic devices.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: September 3, 2024
    Assignee: Merck Patent GmbH
    Inventors: Ilona Stengel, Florian Maier-Flaig, Philipp Harbach, Elvira Montenegro, Aurélie Ludemann
  • Semiconductor aqueous composition and use of the same
    Patent number: 12077727
    Abstract: [Problem] To provide a semiconductor aqueous composition capable of preventing a pattern collapse and suppressing a bridge defect. [Means for Solution] A semiconductor aqueous composition comprising a single or plurality of surfactant(s) having a monovalent anion part represented by formula (I): Chain 1-X1—X2-Chain 2 (I) wherein, X1 and X2 are each independently —C(=0)- or —S(=0)2-, and Chain 1 and Chain 2 are each independently a linear or branched C1-20 alkyl, wherein one or more H in said C1-20 alkyl are replaced by F, and one or more methylenes in Chain 1 may be replaced by -0-, with the proviso that Chain 1 and Chain 2 may be bonded to form a ring structure) and a monovalent cation part other than hydrogen ion; and water.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: September 3, 2024
    Assignee: Merck Patent GmbH
    Inventors: Kazuma Yamamoto, Maki Ishii, Tatsuro Nagahara
  • Tubing connectors
    Patent number: 12078273
    Abstract: The disclosure herein relates to a flow path comprising half clamps 1 having an interior surface surrounding a flexible tubing 3 connection with a barb adapter 3, when assembled may be placed within a clamshell reduce or prevent deformation of the flexible tubing.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: September 3, 2024
    Assignee: Merck Patent GmbH
    Inventors: Olivier Flick, Robert Langlois, James Vigna, Christine Crequy, Thomas Coton
  • IL4I1 INHIBITORS AND METHODS OF USE
    Publication number: 20240287022
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof wherein A, E, U, X, Y, Z, R1, R2 and n are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases. Also provided herein are pharmaceutical compositions comprising the compounds of the invention, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier and methods of treatment with the compounds of the invention.
    Type: Application
    Filed: June 23, 2022
    Publication date: August 29, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: BRANDON D. CASH, GEORGE MADALIN GIAMBASU, ANDREW M. HAIDLE, BRETT A. HOPKINS, MATTHEW A. LARSEN, CHARLES A. LESBURG, PING LIU, RYAN QUIROZ, SULAGNA SANYAL, CATHERINE M. WHITE, XIN YAN, XIAO MEI ZHENG
  • NOVEL CRYSTALLINE FORMS OF [(1R)-2-(1-BENZOFURAN-3-YL)-1-{[(1S,2R,4R)-7-OXABICYCLO[2.2.1]HEPTAN-2-YL]FORMAMIDO}ETHYL]BORONIC ACID, ADDUCTS THEREOF, AND PROCESSES TO OBTAIN
    Publication number: 20240287102
    Abstract: A solid form of [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, hydrates, solvates, and/or adducts thereof can be used as LMP7 inhibitors. The solid form can be a trimeric crystalline anhydrous form characterized by two or more 2? XRPD peaks at 6.5±0.2°, 11.2±0.2°, 17.1±0.2°, 19.6±0.2°, and 21.9±0.2° degrees.
    Type: Application
    Filed: July 28, 2022
    Publication date: August 29, 2024
    Applicant: Merck Patent GmbH
    Inventors: Delia-Maria GRUIA, Markus Klein, Michael Lange
  • PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
    Publication number: 20240287124
    Abstract: The present invention is directed to prodrugs of compound A: which are nucleoside reverse transcriptase translocation inhibitors (NRTTI) and are useful in the inhibition of HIV reverse transcriptase. The present invention also relates to the use of these compounds for prophylaxis of infection by HIV, treatment of infection by HIV, and prophylaxis, treatment, and delay in the onset or progression of AIDS and/or AIDS-related complexes.
    Type: Application
    Filed: January 26, 2024
    Publication date: August 29, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Mark W. Embrey, Jay A. Grobler, Mark E. Layton, Izzat T. Raheem
  • VHH-BASED NKP30 BINDERS
    Publication number: 20240287177
    Abstract: VHH-based NKp30 binders are provided having favorable characteristics. Moreover, pharmaceutical compositions including such a compound are produced and methods of medical treatment with such compounds and pharmaceutical compositions are developed. In a compound including a VHH antibody domain or fragment thereof, the VHH antibody domain or fragment thereof can have complementary determining regions CDR1, CDR2, and CDR3 of one of VHH1 to VHH16, or a humanized modification thereof, or a modification involving replacement, addition, and/or deletion of up to three amino acids in each complementary determining region.
    Type: Application
    Filed: June 22, 2022
    Publication date: August 29, 2024
    Applicant: Merck Patent GmbH
    Inventors: Stefan ZIELONKA, Lars Toleikis, Simon Krah, Lukas Pekar, Andreas Evers
  • Materials for electronic devices
    Patent number: 12071405
    Abstract: The present application relates to compounds of formula (I) containing a group selected from amino groups, bridged amino groups and carbazole groups, to processes for preparation thereof, and to the use thereof in electronic devices, and in particular OLEDs.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: August 27, 2024
    Assignee: Merck Patent GmbH
    Inventors: Elvira Montenegro, Teresa Mujica-Fernaud, Florian Maier-Flaig, Frank Voges
  • Human genetic markers associated with response to treatments that target clostridium difficile toxin B
    Patent number: 12071666
    Abstract: The present invention provides genetic markers on human chromosome 6 that are associated with a beneficial response to a treatment that targets Clostridium difficile (C. difficile) toxin B (TcdB), e.g. a TcdB antibody. These TcdB treatment response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment that targets TcdB in methods of treating patients having a disease susceptible to treatment with a TcdB antibody, and in methods for selecting the most appropriate therapy for such patients. The invention also provides antibodies, drug products, and kits useful with the TcdB Treatment response markers of the invention.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 27, 2024
    Assignees: Merck Sharp & Dohme LLC, Beijing Genomics Institute at Shenzhen
    Inventors: Peter M. Shaw, Devan V. Mehrotra, Rebecca L. Blanchard, Judong Shen, Robin Mogg, Mary Beth Dorr, Junhua Li, Xun Xu
  • Display device, production and use thereof
    Patent number: 12071565
    Abstract: The present invention relates to a display device, in particular a backlit display device having a visible side and a back side, which appears opaque in colour and texture on viewing of the visible side without backlighting, but, with the backlighting switched on, is sufficiently transparent that the transmission of information by the light source from the back side is possible, and to the production of a display device of this type and to the use thereof.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: August 27, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Sabine Eberle, Udo Gumsheimer
  • COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA
    Publication number: 20240277711
    Abstract: cMET inhibitors can be used in the treatment of glioblastoma, including disseminated glioblastoma harboring MET amplification.
    Type: Application
    Filed: June 2, 2022
    Publication date: August 22, 2024
    Applicant: Merck Patent GmbH
    Inventors: Claudia-Nanette GANN, Ilhan Celik, Nazanin Majd, John Frederick de Groot, Michael Weller
  • CONTINOUS IMPREGNATION OF ACTIVE PHARMACEUTICAL INGREDIENTS ONTO POROUS CARRIERS
    Publication number: 20240277645
    Abstract: The disclosed technology relates to a continuous impregnating process of active pharmaceutical ingredients (API) onto porous carriers, a continuous impregnation process for making impregnated porous carrier particles and pharmaceutical dosage forms comprising impregnated porous carrier particles, impregnated porous carrier particles and pharmaceutical dosage forms comprising impregnated porous carrier particles prepared by the continuous impregnation process.
    Type: Application
    Filed: June 13, 2022
    Publication date: August 22, 2024
    Applicants: MERCK PATENT GMBH, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Fernando J. MUZZIO, Benjamin J. GLASSER, Thamer A. OMAR, Andrés D. ROMÁN-OSPINO, Gudrun BIRK
  • REACTIVE MESOGENS
    Publication number: 20240279550
    Abstract: Reactive mesogens (RMs) derived from tolane, mixtures and formulations comprising them, polymers obtained from such RMs and RM mixtures, and the use of the RMs, RM mixtures and polymers in optical or electrooptical components or devices.
    Type: Application
    Filed: May 4, 2022
    Publication date: August 22, 2024
    Applicant: Merck Patent GmbH
    Inventors: Kevin Adlem, Owain Llyr Parri, Alex Davis, Stephen Mulcahy, Philipp Wucher, Beate Schneider
  • Substrate cleaning solution, and using the same, method for manufacturing cleaned substrate and method for manufacturing device
    Patent number: 12068150
    Abstract: [Problem] To obtain a substrate cleaning solution capable of cleaning a substrate and removing particles. [Means for Solution] The present invention is a substrate cleaning solution comprising an insoluble or hardly soluble solute (A), a soluble solute (B), and a solvent (C).
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: August 20, 2024
    Assignee: Merck Patent GmbH
    Inventors: Takafumi Kinuta, Tatsuro Nagahara, Yuko Horiba